Coxsackie viruses are enteroviruses belonging to the Picornavirus family, which is comprised of strains A and B as well as various serotypes A1-22, 24, and B1-6. Following incubation, a variety of well known diseases can manifest themselves within the host. Coxsackie A is commonly associated with hand, foot, and mouth disease, which primarily affects children younger than 10 years of age. In rare cases, Coxsackie infections may produce mild or subclinical symptoms, yet most infections trigger the onset of flu-like ailments but may include symptoms of other diseases along the lines of pneumonia, hepatitis, and meningitis.

Coxsackievirus A7 (CVA7) is a rarely detected and poorly characterized virus that belongs to the Enterovirus A species and has three strains: Parker, USSR, and 275/58. Despite a difference in pathogenicity among the three strains, they can all be typed by CVA7-specific neutralizing antibodies. CVA7 is most closely related to CVA14, CVA16, and Enterovirus 71 (EV71), and is associated with hand, foot and mouth disease (HFMD). CVA7 is neurotropic and can cause paralytic poliomyelitis. CVA7 was widely detected in the 1950s and 1960s during paralytic epidemics.

Coxsackie viruses are enteroviruses belonging to the Picornavirus family, which is comprised of strains A and B as well as various serotypes A1-22, 24, and B1-6. Following incubation, a variety of well known diseases can manifest themselves within the host. Coxsackie A is commonly associated with hand, foot, and mouth disease, which primarily affects children younger than 10 years of age. In rare cases, Coxsackie infections may produce mild or subclinical symptoms, yet most infections trigger the onset of flu-like ailments but may include symptoms of other diseases along the lines of pneumonia, hepatitis, and meningitis.

Coxsackie B-1 Antibody (Ab) is a specific immunological marker used in the detection of previous or ongoing infections caused by the Coxsackie B-1 virus, a member of the Enterovirus genus within the Picornaviridae family. This virus is known for its role in a variety of clinical syndromes, ranging from mild febrile illnesses to more severe conditions such as myocarditis, pericarditis, and aseptic meningitis. The presence of Coxsackie B-1 Ab, particularly IgM and IgG classes, in serum samples is indicative of the immune response triggered by the body against this pathogen. IgM antibodies usually suggest a recent acute infection, appearing early in the course of the disease and declining as the infection resolves. In contrast, IgG antibodies develop later and can persist for years, indicating past exposure and possibly conferring immunity. The detection of these antibodies is crucial for epidemiological surveillance, diagnosis, and understanding the immunopathology of Coxsackie B-1 virus infections. Advanced serological assays, including enzyme-linked immunosorbent assay (ELISA) and neutralization tests, are employed for accurate and sensitive detection of Coxsackie B-1 Ab, playing a significant role in clinical diagnosis and in differentiating this infection from other enteroviral diseases with similar clinical presentations.

Coxsackie B-2 Antibody (Coxsackie B-2 Ab) is a specific immunoglobulin marker indicative of exposure to the Coxsackie B-2 virus, a member of the enterovirus family and one of the distinct serotypes within the Coxsackie B virus group. This serotype is known for its role in various clinical manifestations ranging from mild, flu-like symptoms to more severe conditions like myocarditis, pericarditis, and pancreatitis. The presence of Coxsackie B-2 antibodies, detectable through serological assays, is crucial in the diagnosis and epidemiological tracking of these infections. 

Coxsackie B-3 antibody (Coxsackie B-3 Ab) plays a pivotal role in the immunological response to Coxsackie B-3 virus, a significant member of the Enterovirus genus within the Picornaviridae family. This virus is known for its involvement in various clinical syndromes, ranging from mild gastrointestinal and respiratory illnesses to more severe conditions like myocarditis, pericarditis, and pancreatitis. The Coxsackie B-3 Ab is a specific antibody formed in response to infection by the Coxsackie B-3 virus, and its detection is crucial for the accurate diagnosis and epidemiological study of the virus.

Coxsackie B-4 antibody (Coxsackie B-4 Ab) is a specific immunoglobulin marker indicative of exposure to the Coxsackie B-4 virus, a member of the Enterovirus genus within the Picornaviridae family. This virus is known for its role in various human diseases, ranging from mild febrile illnesses to more severe conditions such as myocarditis, pancreatitis, and aseptic meningitis. The presence of Coxsackie B-4 Ab is particularly significant in the context of research into the etiology of type 1 diabetes mellitus; there is accumulating evidence suggesting that Coxsackie B-4 may act as a trigger in genetically predisposed individuals, potentially initiating or accelerating pancreatic beta-cell destruction.

Coxsackie B-5 Antibody (Coxsackie B-5 Ab) is a specific marker used in the serological diagnosis of infections caused by the Coxsackie B-5 virus, one of the several serotypes of the Coxsackie B viruses belonging to the Enterovirus genus. The presence of Coxsackie B-5 Ab in a patient's serum is indicative of an immune response to this particular serotype, which is known for its role in a range of acute and chronic illnesses.

Coxsackie B-6 Ab, or Coxsackie B-6 antibody, is a significant marker in the medical diagnosis and study of infections caused by the Coxsackie B-6 virus, a member of the Enterovirus genus within the Picornaviridae family. This specific antibody is part of the immune response to the Coxsackie B-6 virus, which is known for causing a spectrum of diseases, ranging from mild gastrointestinal distress to more severe conditions like myocarditis, pericarditis, and even pancreatitis. The presence of Coxsackie B-6 Ab in a patient's blood is indicative of either a current or past infection with this virus.

What is Coxsackie Virus – IgG?

Coxsackie viruses are a group of enteroviruses that can cause a variety of illnesses, ranging from mild to serious. These viruses are divided into Group A and Group B, each associated with different clinical conditions. Group A viruses often cause hand, foot, and mouth disease, while Group B viruses can lead to viral myocarditis, pericarditis, or aseptic meningitis.

The IgG antibody test for Coxsackie virus detects long-term immune response to the virus. IgG antibodies typically develop several weeks after infection and remain in the bloodstream for months or even years, indicating past exposure or infection.

What Does a Medium Result Mean?

A medium IgG result indicates a moderate level of antibodies, which may reflect:

• A recent past infection with declining antibody levels

• An incomplete or borderline immune response

• A nonspecific or cross-reactive finding, particularly in the absence of symptoms

This result should be interpreted alongside your clinical history, symptoms, and any corresponding IgM antibody results, which reflect current or recent infection.

Coxsackie-IgG Type A7 (IFT) detects long-lasting antibodies to Coxsackievirus A7 and is best viewed as evidence of past exposure, not proof of a current infection. Because IFT is assay-specific and enteroviruses can cross-react, use your lab’s cutoffs and clinical context. For suspected acute disease, pair serology with PCR/NAAT (throat/stool/CSF/lesion) and/or look for a fourfold rise in IgG on paired sera 2–4 weeks apart; IgM may support recent exposure but is less reliable than PCR for timing. In the absence of symptoms, elevated IgG usually needs no treatment. If symptomatic, care is typically supportive while ruling in/out other causes.

Coxsackie-IgG Type B1 (IFT) detects long-lasting antibodies to Coxsackievirus B1 and mainly indicates past exposure, not an active infection. Because IFT methods and cutoffs differ and cross-reactivity among enteroviruses can occur, rely on your lab’s ranges and your clinical picture. For suspected acute disease, pair serology with PCR/NAAT (throat/stool/CSF/lesion) and consider paired sera to look for a fourfold IgG rise over 2–4 weeks; IgM may suggest recent exposure but is less specific than PCR for timing. Coxsackie B viruses can involve the heart (myopericarditis), meninges, or pleura/pancreas—seek evaluation if symptoms fit. In the absence of symptoms, an elevated IgG usually needs no treatment.

The Crab marker measures IgG antibodies to proteins found in crab. Results are reported as none detected, very low, low, moderate, or high. These levels reflect immune exposure and recognition rather than a true shellfish allergy. Interpretation should consider symptom history, frequency of shellfish intake, and overall immune health.